How do you market a telehealth weight loss clinic?

Own the searches patients use to choose a provider (programme, comparison, cost, eligibility, state), defend the brand SERP, earn authority from health and business publishers, and keep every claim inside what your counsel allows. Run paid where the economics work and report organic's share of new patients against it.

How to start a GLP-1 business?

Licensing, prescribing, sourcing and compounding are questions for your medical and legal advisers. From a marketing point of view, the businesses that survive their first year have more than one acquisition channel and a compliance perimeter written down before the first page is published.

Is it legal to sell compounded semaglutide?

That is a legal question that depends on the pharmacy, the prescriber, the state and the current FDA position, all of which changed in 2025 and 2026. We keep a dated brief on the compounded-product picture and we treat it as changeable; the legal boundary is your counsel's.

Can we advertise GLP-1 programmes on Meta and Google?

Both platforms allow some health advertising under restrictions: Meta requires 18+ targeting and bans personal-attribute and body-image framing; Google gates prescription-drug and restricted-drug advertising behind certification. Paid is possible and expensive. Organic is the layer that does not re-auction.

GLP-1 Marketing in 2026: CAC, Channels, Restrictions and the Organic Layer

GLP-1 marketing in 2026 is an expensive auction with a regulator watching. Meta and Google allow restricted health advertising at rising cost; affiliates and comparison networks take a margin on every patient; FDA has cited website copy in 55 warning letters this year and the FTC has acted on claims, testimonials, subscriptions and health data. The durable move is to keep the paid channels and build the organic layer underneath them: the programme, comparison, cost and brand searches nobody re-auctions every morning.

The channels, honestly

Rented

Meta: allowed with 18+ targeting and strict creative rules; CAC rising
Google Ads: prescription-drug and restricted-term certification; expensive clicks
Affiliates and comparison networks: margin on every patient, claims risk transferred to you
Influencers: reach with platform and claims exposure

Durable

Programme, treatment and cost rankings
Comparison visibility
State and local demand
Brand SERP
Informational authority that feeds AI answers
Retention with consent

What FDA and the FTC have cited

FDA's March and June 2026 letters to 55 telehealth companies cite website promotional copy: claims that equate compounded products (which are not FDA-approved) with approved drugs, language implying agency approval or evaluation, and company-branded products that obscure who compounds them. The FTC's NextMed order (December 2025) covered unsubstantiated weight-loss claims, fake testimonials and undisclosed costs; its July 2026 complaint against a large telehealth brand covered health-data handling and subscription practices. Every one of these is a page, a title, a comparison table or a pixel: marketing decisions with regulatory consequences.

Why the organic layer is the asset

Our September 2026 sample shows the head terms held by pharmacies, platforms and media at high authority, and AI Overviews on most commercial queries. That is where paid is most expensive and organic is slowest. Comparison, cost, eligibility, state and brand demand is where an operator can win in months, and where every organic patient displaces a bought one. We report organic's share of new patients alongside paid so the shift is a number.

The GLP-1 marketing plan we would run

Map commercial demand for your programmes and the comparison and cost queries patients use to choose.
Find the near-wins already on the site and move them first.
Build the programme, comparison and cost pages for a regulator as well as a reader.
Earn authority from health and business publishers; defend the brand SERP.
Run a standing wording check with a dated rule store; route anything amber or red to counsel.
Keep the paid channels, and watch organic's share of new patients climb in the same report.

Sources

Meta Health and Wellness ad standard (changelog 2026-07-22) — https://transparency.meta.com/policies/ad-standards/restricted-goods-services/health-wellness/
Google Ads: Prescription drug services — https://support.google.com/adspolicy/answer/15598647
FDA warning letters to telehealth companies (2026-03-03 and 2026-06-16) — https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1-s
FTC final order against NextMed (2025-12) — https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive

GLP-1SEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice, or advice to patients. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.

GLP-1 marketing in 2026: keep the paid channels, build the moat underneath